News & Events

In this section

Instem Unveils New Additions to its Leading Computational Toxicology Software Suite

New functionality along with Enhanced Models to Deliver More Efficient and Comprehensive Predictions in Chemical Safety

PHILADELPHIA, PA – (BUSINESS WIRE) – November 2, 2022 Instem, a leading provider of IT solutions and services to the global life sciences market, announced today that the latest edition of its powerful Leadscope Model Applier Computational Toxicology software solution has been released.  

This latest update includes new functionality to provide a more seamless experience when performing a Read-Across, as well as new and updated predictive models to support the increasing market need for in silico solutions. The new release will also be used as part of the recently introduced Predict™ technology-enabled service for nitrosamine carcinogenicity risk assessment.

Renowned for their advanced informatics and prediction technology, together with comprehensive database solutions, Instem’s in silico solutions enable organizations around the world to effectively unlock valuable knowledge contained in both public and proprietary sources of research data. Clients can also access well over 600,000 toxicology studies for more than 200,000 chemicals, enabling fast, accurate, defendable and regulatory-accepted predictions.

Core features of the 2022 software release include:

  • NEW Read-Across Tool – a single and easy-to-use tool for searching analogs and performing read-across, while providing direct access to an extensive toxicology database.
  • Leadscope Advanced™ Edition – includes advanced functionality and now available online, eliminating the need to invest in computer hardware and enabling quicker, easier access to new software updates.
  • UPDATED Genetox Expert Alerts – The Leadscope Expert Alerts suite for bacterial mutagenicity, widely used for ICH M7 regulatory submissions, has been updated to enhance predictivity and interpretation.
  • UPDATED Sensitization Models and Alerts - Updated models and alerts for the assessment of skin sensitization; including models to predict strong or extreme sensitizers formed on a growing database.
  • NEW Acute Toxicity Predictive Models – New expert predictive models to predict acute lethality in dermal, oral and inhalation studies, based on research of over 175,000 chemicals with acute toxicity data.  
  • NEW Statistical Models and Expert Alerts to support the prediction of eye irritation and corrosion.
  • NEW and UPDATED Statistical-Based Models to support the assessment of endocrine activity, drug permeability across the blood-brain barrier* (supporting abuse liability), and cardiac toxicity* (*developed by the US FDA under the Research Collaboration Agreement).

Dr. Glenn Myatt, VP Informatics, Instem said “We are delighted to introduce the 2022 Computational Toxicology software release, which will further strengthen the ongoing demand for reliable alternatives to traditional testing methods.”

Dr. Myatt continued “This latest release is highly anticipated and will give both existing and prospective clients expanded support for regulatory guidelines, drug discovery, classification and labeling as well as occupational toxicology. Throughout the lifecycle of the release, we have been working in close collaboration with our clients, and feedback has been extremely positive.”

Instem has developed a comprehensive program to help raise awareness of this important 2022 software release through on-demand demonstrations and presentations at key industry events including the ACT 43rd Annual Meeting, November 13th – 16th, Denver, Colorado.  

To be added to the release alert list and be one of the first to receive a copy of the on-demand presentation, please email  

About Instem

A global provider of leading software solutions and scientific insight services, Instem is helping clients bring their life enhancing products to market faster.

We enable organizations in the life sciences to more efficiently collect, report and submit high quality regulatory data, while offering them the unique ability to generate new knowledge through the extraction and harmonization of actionable scientific information.

Across the entire drug development value chain, every day Instem solutions are meeting the rapidly expanding needs of life science organizations for data-driven decision making, leading to safer, more effective products.

Instem supports its global roster of clients through offices in the United States, United Kingdom, France, Switzerland, Japan, China, and India.

Press Contacts: 

Julie Jones, Marketing Director

Pooja Pankhania, Marketing Manager – In Silico Solutions